Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SELL | P14151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511327 | 0.95 | MRGPRX4 (0.45) | MRGPRX4GPR35CA1CA2CA12 | |
| SCHEMBL21151179 | 0.89 | MRGPRX4 (0.43) | MRGPRX4GPR35CA1CA2CA12 | |
| SCHEMBL2562951 | 0.87 | CA12 (0.60) | MRGPRX4GPR35CA1CA2CA12 | |
| SCHEMBL505097 | 0.85 | HCAR1 (0.53) | — | |
| SCHEMBL5225001 | 0.85 | TPMT (0.43) | MRGPRX4GPR35CA1CA2CA12 | |
| SCHEMBL13674520 | 0.85 | KDM4E (0.42) | MRGPRX4GPR35CA1CA2CA12 | |
| SCHEMBL2160802 | 0.85 | TPMT (0.61) | MRGPRX4GPR35CA1CA2CA12 | |
| SCHEMBL5222297 | 0.85 | POLB (0.42) | MRGPRX4GPR35CA1CA2CA12 | |
| SCHEMBL2565282 | 0.85 | TPMT (0.61) | MRGPRX4GPR35TPMTALOX15TSHR | |
| SCHEMBL14395100 | 0.85 | MRGPRX4 (0.40) | MRGPRX4GPR35CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0052437-A1 | Antibacterial compounds, processes for their preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1982-05-26 | — | — | EP | claimed |
| CN-118978457-B | Pretreatment method of MXDA raw material | 山东联盟化工股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118978457-A | Pretreatment method of MXDA raw material | 山东联盟化工股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118076592-A | SHP2 inhibitor, pharmaceutical composition comprising same and use thereof | 北京泰德制药股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-115160285-B | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-115160285-A | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-111333545-B | 3, 6-dioxocyclohexyl-1, 4-diene-1, 2-dinitrile derivative, preparation and application thereof | 华中科技大学 | 2021-03-26 | — | — | CN | disclosed |
| CN-111333545-A | 3, 6-dioxocyclohexyl-1, 4-diene-1, 2-dinitrile derivative, preparation and application thereof | 华中科技大学 | 2020-06-26 | — | — | CN | disclosed |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | LIPOSCIENCES, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2017-08-10 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030216577-A1 | Preparation of aromatic and heteroaromatic carboxylic acids by catalytic ozonolysis | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-11-20 | — | — | US | disclosed |
| EP-1362840-A1 | Process for the preparation of aromatic and heteroaromatic carboxylic acids via catalytic ozonolysis | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-11-19 | — | — | EP | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-5080832-A | 4-aminobenzoic acid and dinitro- or decyanobenzoic acid compounds; coherent radiation | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1992-01-14 | — | — | US | disclosed |
| US-4992214-A | Crystalline; with intermolecular hydrogen bonding | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0052437-A1 | Antibacterial compounds, processes for their preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1982-05-26 | — | — | EP | disclosed |
| US-3995044-A | Pyridine carboxylic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | NCL, PHOSPHO1, POLN | MRGPRX4 3632/4885GPR35 3175/4885CA1 4385/4885 |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | MRGPRX4 3569/4885GPR35 4050/4885CA1 3523/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | MRGPRX4 297/4885GPR35 101/4885CA1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.